Skip Nav Destination
Close Modal
Update search
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Date
Availability
Can't find what you're looking for? Search for content across all of AAP's sites.
1-20 of 55
RSV
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
News
Published: August 08, 2024
TOPICS:
Fetus/Newborn Infant,
Infectious Diseases,
Maternal and Fetal Medicine,
RSV,
Vaccine/Immunization
Abstract
Nirsevimab was 91%-98% effective at preventing RSV hospitalizations.
News
Published: July 24, 2024
TOPICS:
Fetus/Newborn Infant,
Hematology/Oncology,
Infectious Diseases,
Ophthalmology,
Pharmacology,
RSV,
Vaccine/Immunization
Abstract
Supply chain issues, manufacturing difficulties and increased demand have contributed to supply issues with a variety of drugs, immunizations and medical devices.
News
Published: July 01, 2024
Abstract
Feedback from pediatricians is crucial when the AAP advocates for new payment code values, as in new rates for administration and counseling of nirsevimab.
News
Published: July 01, 2024
TOPICS:
Infectious Diseases,
Respiratory Tract,
RSV,
Vaccine/Immunization,
COVID-19,
Diversity, equity and inclusion
Abstract
The COVID-19 pandemic emphasized how inequities based on race and socioeconomic status impact the risk of infection and infection-related outcomes in children.
News
Published: June 28, 2024
Abstract
A federal vaccine committee called nirsevimab’s effectiveness “outstanding.”
News
Published: May 08, 2024
Abstract
Providers will have until May 17 to submit their forecasted needs for RSV immunization nirsevimab next season.
News
Published: April 12, 2024
Abstract
The new list price per dose is $519.75, which is a 5% increase.
News
Published: March 07, 2024
Abstract
RSV is the leading cause of hospitalization in infants.
News
Published: March 01, 2024
TOPICS:
Influenza,
RSV,
Vaccine/Immunization,
COVID-19
Abstract
The Centers for Disease Control and Prevention has updated guidance for those infected with respiratory viruses, including COVID-19, flu and RSV.
News
Published: March 01, 2024
Abstract
Families can use the test results to take action for their child’s health or seek their pediatrician’s advice .
News
Published: February 02, 2024
Abstract
Program participants will work with Sanofi to forecast their needs for next season and reserve doses of nirsevimab. The company hopes to mitigate the supply issues that plagued this year’s launch.
News
Published: January 23, 2024
Abstract
While errors are rare, at least 25 children under 2 years have been given an adult vaccine, while 128 pregnant people have been given a vaccine not approved during pregnancy.
News
Published: January 05, 2024
Abstract
Clinicians can return to the original recommendations for using RSV immunization nirsevimab (Beyfortus) as supplies increase.
News
Published: December 14, 2023
Abstract
The additional supplies will include both 50 mg and 100 mg doses and will be distributed in January.
News
Published: December 05, 2023
TOPICS:
Advocacy,
Developmental/Behavioral Issues,
Fetus/Newborn Infant,
Infectious Diseases,
Influenza,
RSV,
Vaccine/Immunization,
COVID-19,
Diversity, equity and inclusion
Abstract
From new research to practice recommendations to advocacy efforts, AAP News has been helping pediatricians stay up to date on child health issues.
News
Published: November 16, 2023
Abstract
The schedules incorporate policies approved over the past year and tweaks to improve clarity and readability.
News
Published: November 16, 2023
Abstract
The CDC is releasing more than 77,000 of the 100 mg doses of nirsevimab (Beyfortus).
News
Published: November 13, 2023
Abstract
New CPT codes have been approved for the administration of nirsevimab (Beyfortus) for the prevention of RSV.
News
Published: November 09, 2023
Abstract
Sanofi paused ordering for 50 mg doses but plans to reopen them Nov. 16 with limited allocation.
News
Published: November 07, 2023
Abstract
Sanofi plans to reopen its ordering system for RSV immunization nirsevimab (Beyfortus) on Nov. 16, but only customers with an allocation will be able to place a new order.
1
